AmpliMed

Cancer drugs licensed from University of Arizona Foundation

Published in Pharma Law Weekly, September 6th, 2005

AmpliMed and UAF Technologies and Research, LLC, (UTR) announced that AmpliMed has licensed from UTR certain patents, intellectual property and other assets associated with a portfolio of compounds that has been tested in preclinical studies and may have the potential to treat cancer and certain viral diseases.

In particular, one of the compounds in the portfolio, FB642, has shown promise in early clinical trials as an anticancer drug. Under the license agreement, AmpliMed will take over development of FB642 from UTR and is responsible for maintenance of the FB642 intellectual property portfolio. In return, UTR will receive equity in AmpliMed along with cash payments on...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Law Weekly

Source: Pharma Law Weekly (2005-09-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry